"The
Report Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical
Trials Review, H2, 2016 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
GlobalData's clinical trial
report, Relapsing
Remitting Multiple Sclerosis (RRMS) Global
Clinical Trials Review, H2, 2016" provides an overview of
Relapsing Remitting Multiple Sclerosis (RRMS) clinical trials
scenario. This report provides top line data relating to the clinical
trials on Relapsing Remitting Multiple Sclerosis (RRMS). Report
includes an overview of trial numbers and their average enrollment in
top countries conducted across the globe. The report offers coverage
of disease clinical trials by region, country (G7 & E7), phase,
trial status, end points status and sponsor type. Report also
provides prominent drugs for in-progress trials (based on number of
ongoing trials). GlobalData Clinical Trial Reports are generated
using GlobalDatas proprietary database - Pharma eTrack Clinical
trials database. Clinical trials are collated from 80+ different
clinical trial registries, conferences, journals, news etc across the
globe. Clinical trials database undergoes periodic update by dynamic
process.
The report enhances the
decision making capabilities and helps to create an effective counter
strategies to gain competitive advantage.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/805622
Scope
- The report provides a
snapshot of the global clinical trials landscape
- Report provides top level
data related to the clinical trials by Region, Country (G7 & E7),
Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top
companies involved and enlists all trials (Trial title, Phase, and
Status) pertaining to the company
- The report provides all the
unaccomplished trials (Terminated, Suspended and Withdrawn) with
reason for unaccomplishment
- The Report provides
enrollment trends for the past five years
- Report provides latest news
for the past three months
Reasons to buy
- Assists in formulating key
business strategies with regards to investment
- Helps in identifying
prominent locations for conducting clinical trials which saves time
and cost
- Provides top level analysis
of Global Clinical Trials Market which helps in identifying key
business opportunities
- Supports understanding of
trials count and enrollment trends by country in global therapeutics
market
- Aids in interpreting the
success rates of clinical trials by providing a comparative scenario
of completed and uncompleted (terminated, suspended or withdrawn)
trials
- Facilitates clinical trial
assessment of the indication on a global, regional and country level
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average
Enrollment by Country 7
Top Five Countries Contributing
to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing
to Clinical Trials in Europe 10
Top Countries Contributing to
Clinical Trials in North America 11
Top Five Countries Contributing
to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing
to Clinical Trials in Central and South America 13
Clinical Trials by G7
Countries: Proportion of Relapsing Remitting Multiple Sclerosis
(RRMS) to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7
Countries 15
Clinical Trials in G7 Countries
by Trial Status 16
Clinical Trials by E7
Countries: Proportion of Relapsing Remitting Multiple Sclerosis
(RRMS) to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7
Countries 18
Clinical Trials in E7 Countries
by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status
22
Clinical Trials by End Point
Status 23
Subjects Recruited Over a
Period of Time 24
Clinical Trials by Sponsor Type
25
Prominent Sponsors 26
Top Companies Participating in
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical
Trials 27
Prominent Drugs 28
Latest Clinical Trials News on
Relapsing Remitting Multiple Sclerosis (RRMS) 29
Jun 28, 2016: Coherus Announces
Positive Phase 2B Efficacy Data On Novel Oral Therapy In Relapsing
Remitting Multiple Sclerosis 29
Jun 03, 2016: Novartis data
show Gilenya had significantly greater patient retention compared to
iDMTs in relapsing-remitting MS 29
Jun 03, 2016: Arrien
Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a
New Agent for Treatment of Multiple Sclerosis 30
May 31, 2016: GeNeuro Announces
First Patients Treated in Phase 2b Study for Multiple Sclerosis 31
May 25, 2016: Merck to Present
Data on Rebif (interferon beta-1a) for Multiple Sclerosis at 2nd
Congress of the European Academy of Neurology 31
May 25, 2016: Merck to Present
Data on Cladribine Tablets for Multiple Sclerosis at 2nd Congress of
the European Academy of Neurology 32
May 03, 2016: TG Therapeutics
Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101
(Ublituximab) 33
Apr 22, 2016: Daclizumab
Demonstrates Significant, Sustained Improvements In Cognition
Compared To Interferon Beta-1A IM 33
Apr 20, 2016: Data Presented at
AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive
Outcomes and the Reversibility of Its Targeted Mechanism of Action 34
Clinical Trial Profile
Snapshots 36
Appendix 517
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment